Last reviewed · How we verify
VRD for first-cycle induction therapy
VRD is a combination regimen of bortezomib, lenalidomide, and dexamethasone that targets proteasome inhibition and cereblon-mediated degradation to induce apoptosis in multiple myeloma cells.
VRD is a combination regimen of bortezomib, lenalidomide, and dexamethasone that targets proteasome inhibition and cereblon-mediated degradation to induce apoptosis in multiple myeloma cells. Used for Multiple myeloma, first-cycle induction therapy.
At a glance
| Generic name | VRD for first-cycle induction therapy |
|---|---|
| Also known as | Bortezomib(V), Lenalidomide(R), Dexamethasone(D) |
| Sponsor | The First Affiliated Hospital of Soochow University |
| Drug class | Proteasome inhibitor + immunomodulatory agent + corticosteroid combination |
| Target | 26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Bortezomib inhibits the 26S proteasome, leading to accumulation of pro-apoptotic proteins and cell cycle arrest. Lenalidomide binds cereblon and promotes degradation of IKZF1 and IKZF3, enhancing T-cell proliferation and NK cell activation. Dexamethasone provides additional anti-myeloma and immunomodulatory effects. Together, these agents synergistically induce myeloma cell death and enhance immune-mediated tumor control.
Approved indications
- Multiple myeloma, first-cycle induction therapy
Common side effects
- Peripheral neuropathy
- Thrombocytopenia
- Anemia
- Infection
- Fatigue
- Nausea/vomiting
- Diarrhea
Key clinical trials
- Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (PHASE2)
- Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (PHASE2)
- A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
- Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) (PHASE2)
- UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma (PHASE3)
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection (PHASE4)
- Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (PHASE2)
- Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: